Clinical study assessing the safety, tolerability, and pharmacokinetics of intravenous AZD5099 in healthy subjects

Study identifier:D0910C00015

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment on Hold

Official Title

A Phase I, Single-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics in Intravenous AZD5099 after Single Ascending Doses in Healthy Male and Female Subjects

Medical condition

Healthy

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD5099, Placebo

Sex

All

Actual Enrollment

80

Study type

Interventional

Age

18 Years - 55 Years

Date

Study Start Date: 01 May 2011
Estimated Primary Completion Date: 01 Dec 2011
Estimated Study Completion Date: 01 Dec 2011

Study design

Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Double Blind
Primary Purpose: Basic Science

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria